Remove tag early-access
article thumbnail

Free access to Zolgensma curbed, says Novartis

pharmaphorum

Novartis’ programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company. ” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1 Pause in UK access.

article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

This is not the first treatment to come with a high price tag. Access to oncology medicines varies across countries, and their cost against safety/efficacy is generally perceived as being low, such as in the US. million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

Marketing 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pioneering the Path Pre- and Post-Launch Strategies

PM360

Making the Case for Early Medical Affairs Involvement Early involvement of Medical Affairs in the product lifecycle is not just beneficial—it is mission critical. Most importantly, this global function needs to be integrated as “one team” with “one goal” for the success of the product and access for the patient.

Medical 52
article thumbnail

Cannabinoids receptors: popular preclinical target but banned in 137 countries

Pharmaceutical Technology

Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total. However, access is restricted, requiring a special permit given under exceptional circumstances. This is closely followed by CB2 receptors in second place.

Medical 98
article thumbnail

[Podcast] COVID Disruption & Its Indelible Mark on Healthcare Marketing

Healthcare Success

Not only that, but many doctors and nurses are choosing to retire early or leave their professions altogether. People are retiring early, dealing with burnout, and removing themselves from rotation due to COVID illness. Early in the pandemic, Alan focused on increased and transparent communication strategies to reach more people. “We

article thumbnail

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. What we now need to do better at is access; both in other countries and within countries beyond the premier centers and big cities…to give access to all patients who could benefit from these advanced therapies.

article thumbnail

Leading innovators in peptide nano-particle conjugates for the pharmaceutical industry

Pharmaceutical Technology

Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity. However, not all innovations are equal and nor do they follow a constant upward trend.